These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22205060)

  • 21. The metabolic syndrome.
    Eckel RH; Grundy SM; Zimmet PZ
    Lancet; 2005 Apr 16-22; 365(9468):1415-28. PubMed ID: 15836891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The metabolic syndrome and its cardiovascular manifestations.
    Sánchez-Torres RJ; Delgado-Osorio H
    Bol Asoc Med P R; 2005; 97(4):271-80. PubMed ID: 16599068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies.
    O'Neill S; O'Driscoll L
    Obes Rev; 2015 Jan; 16(1):1-12. PubMed ID: 25407540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome.
    Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
    Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic syndrome.
    Reaven P
    J Insur Med; 2004; 36(2):132-42. PubMed ID: 15301226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes.
    Barnett AH
    Diab Vasc Dis Res; 2008 Mar; 5(1):9-14. PubMed ID: 18398806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obesity and the metabolic syndrome in the elderly--a mini-review.
    Lechleitner M
    Gerontology; 2008; 54(5):253-9. PubMed ID: 18841025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence, Pathophysiology, and Management of Androgen Deficiency in Men with Metabolic Syndrome, Type 2 Diabetes Mellitus, or Both.
    Taylor SR; Meadowcraft LM; Williamson B
    Pharmacotherapy; 2015 Aug; 35(8):780-92. PubMed ID: 26289308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic syndrome in the prevention of cardiovascular diseases and diabetes--still a matter of debate?
    Ma X; Zhu S
    Eur J Clin Nutr; 2013 May; 67(5):518-21. PubMed ID: 23403882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of different definitions of the metabolic syndrome on the prevalence of organ damage, cardiometabolic risk and cardiovascular events.
    Mancia G; Bombelli M; Facchetti R; Casati A; Ronchi I; Quarti-Trevano F; Arenare F; Grassi G; Sega R
    J Hypertens; 2010 May; 28(5):999-1006. PubMed ID: 20308922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diabetes and the metabolic syndrome--when is it best to intervene to prevent?
    Haffner S
    Atheroscler Suppl; 2006 Apr; 7(1):3-10. PubMed ID: 16504598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macrovascular complications of metabolic syndrome: an early intervention is imperative.
    Tenenbaum A; Motro M; Schwammenthal E; Fisman EZ
    Int J Cardiol; 2004 Nov; 97(2):167-72. PubMed ID: 15458679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic syndrome: is it a syndrome? Does it matter?
    Kahn R
    Circulation; 2007 Apr; 115(13):1806-10; discussion 1811. PubMed ID: 17404171
    [No Abstract]   [Full Text] [Related]  

  • 35. The metabolic syndrome and cardiovascular disease - an ongoing tsunami.
    Hanefeld M; Pistrosch F
    Pediatr Endocrinol Diabetes Metab; 2013; 20(1):5-11. PubMed ID: 25612864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study.
    Smith JD; Borel AL; Nazare JA; Haffner SM; Balkau B; Ross R; Massien C; Alméras N; Després JP
    J Clin Endocrinol Metab; 2012 May; 97(5):1517-25. PubMed ID: 22337910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges associated with metabolic syndrome.
    Spinler SA
    Pharmacotherapy; 2006 Dec; 26(12 Pt 2):209S-217S. PubMed ID: 17125447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 39. The impact of vitamin D deficiency on diabetes and cardiovascular risk.
    Baz-Hecht M; Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2010 Apr; 17(2):113-9. PubMed ID: 20150805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obesity and metabolic disease.
    Koopman RJ; Swofford SJ; Beard MN; Meadows SE
    Prim Care; 2009 Jun; 36(2):257-70. PubMed ID: 19501242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.